Citigroup Maintains Buy on Eli Lilly, Raises Price Target to $525
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Andrew Baum has maintained a 'Buy' rating on Eli Lilly and raised the price target from $360 to $525.
July 26, 2023 | 2:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has maintained a 'Buy' rating on Eli Lilly and raised the price target from $360 to $525, which could positively impact the stock.
The raised price target by Citigroup indicates a positive outlook for Eli Lilly. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100